It is crucial to characterise the HCP population in biopharmaceuticals due to the potential safety risk of introducing foreign proteins into the human immune system. With commonly applied host cell systems such as E. coli,[8] yeast,[9] the mouse myeloma cell line (NS0) [10] and Chinese Hamster Ovary (CHO),[11] the genetic differences between the host system and the human body [12] are many.